- Home
- ESRT vs AGIO Comparison
ESRT vs AGIO Comparison
Compare ESRT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESRT
- AGIO
- Stock Information
- Founded
- ESRT 2011
- AGIO 2007
- Country
- ESRT United States
- AGIO United States
- Employees
- ESRT N/A
- AGIO N/A
- Industry
- ESRT Real Estate Investment Trusts
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- ESRT Real Estate
- AGIO Health Care
- Exchange
- ESRT Nasdaq
- AGIO Nasdaq
- Market Cap
- ESRT 1.2B
- AGIO 1.4B
- IPO Year
- ESRT 2013
- AGIO 2013
- Fundamental
- Price
- ESRT $8.03
- AGIO $33.81
- Analyst Decision
- ESRT Hold
- AGIO Buy
- Analyst Count
- ESRT 2
- AGIO 6
- Target Price
- ESRT $10.65
- AGIO $58.60
- AVG Volume (30 Days)
- ESRT 2.1M
- AGIO 587.8K
- Earning Date
- ESRT 07-23-2025
- AGIO 07-31-2025
- Dividend Yield
- ESRT 1.75%
- AGIO N/A
- EPS Growth
- ESRT 2.67
- AGIO N/A
- EPS
- ESRT 0.30
- AGIO 11.45
- Revenue
- ESRT $762,039,000.00
- AGIO $37,035,000.00
- Revenue This Year
- ESRT $3.70
- AGIO $22.30
- Revenue Next Year
- ESRT $2.56
- AGIO $219.19
- P/E Ratio
- ESRT $26.35
- AGIO $2.92
- Revenue Growth
- ESRT 0.78
- AGIO 25.96
- 52 Week Low
- ESRT $6.56
- AGIO $23.42
- 52 Week High
- ESRT $11.62
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- ESRT 48.44
- AGIO 54.35
- Support Level
- ESRT $7.47
- AGIO $32.53
- Resistance Level
- ESRT $8.76
- AGIO $35.88
- Average True Range (ATR)
- ESRT 0.27
- AGIO 1.30
- MACD
- ESRT -0.09
- AGIO -0.29
- Stochastic Oscillator
- ESRT 43.41
- AGIO 29.27
About ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.